Growth Metrics

Biogen (BIIB) Cash from Operations (2016 - 2025)

Biogen has reported Cash from Operations over the past 17 years, most recently at 511900000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 511900000.0 for Q4 2025, down 32.72% from a year ago — trailing twelve months through Dec 2025 was 2204600000.0 (down 23.33% YoY), and the annual figure for FY2025 was 2204600000.0, down 23.33%.
  • Cash from Operations for Q4 2025 was 511900000.0 at Biogen, down from 1272500000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for BIIB hit a ceiling of 1272500000.0 in Q3 2025 and a floor of 175000000.0 in Q4 2022.
  • Median Cash from Operations over the past 5 years was 609100000.0 (2023), compared with a mean of 582575000.0.
  • Biggest five-year swings in Cash from Operations: crashed 120.88% in 2022 and later surged 5987.2% in 2024.
  • Biogen's Cash from Operations stood at 838300000.0 in 2021, then crashed by 120.88% to 175000000.0 in 2022, then soared by 107.14% to 12500000.0 in 2023, then surged by 5987.2% to 760900000.0 in 2024, then plummeted by 32.72% to 511900000.0 in 2025.
  • The last three reported values for Cash from Operations were 511900000.0 (Q4 2025), 1272500000.0 (Q3 2025), and 160900000.0 (Q2 2025) per Business Quant data.